Trade Alert: The Nvidia Of Biotech
In a few years, that may be how this synthetic DNA company is thought of.
Old Friend, New Structure
We’ve already had one good run this year in a small-cap name that sits at the intersection of synthetic biology and AI-enabled drug discovery. Earlier this month, we took a profitable partial exit on calls we bought last fall, after one of the analysts on our Multibaggers list flagged the stock as a potential “Nvidia of biotech.”
Since then, I’ve wanted to add more exposure. But with the market chopping around and our entry rules tightened (RSI between 40 and 70 and a Chartmill setup score of at least 6), I’ve been waiting for the stock to give us a cleaner spot to reload.
As of yesterday, it finally did.
What Our Multibaggers List Is
For newer readers: our Multibaggers list is a curated subset of our Market Watchers X list. To make the Multibaggers list, a trader or analyst has to have documented 100%+ realized gains over the last year—not just good ideas, but good ideas that were tracked from entry to exit.
This stock has been one of their higher-conviction names for a while, with a thesis that it could be a big winner as AI starts to matter more in biotech.
Why Act Now
What changed this week is that the technical side finally synced up with that fundamental story:
The stock now passes our RSI + setup filter.
It’s still in the fat right tail of our Multibaggers ideas.
And options are pricing in a lot of movement into and past the next earnings report.
For this one, we’re using a hybrid options combo that:
Gives us a long-dated upside tail,
Harvests elevated implied volatility post-earnings,
And keeps our max risk under $750 per contract.
Full details below.
Today’s Multibaggers Trade
AI-enabled biotech / synthetic DNA platform theme
